NEULANDLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.2
| Stock Code | NEULANDLAB | Market Cap | 21,520 Cr. | Current Price | 16,759 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 59.3 | Book Value | 1,454 ₹ | Dividend Yield | 0.07 % | ROCE | 26.6 % |
| ROE | 21.5 % | Face Value | 10.0 ₹ | DMA 50 | 15,375 ₹ | DMA 200 | 14,440 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 213 Cr. | PAT Prev Qtr | 40.4 Cr. |
| RSI | 59.4 | MACD | 544 | Volume | 30,049 | Avg Vol 1Wk | 49,879 |
| Low price | 11,011 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.95 | Debt to equity | 0.16 |
| 52w Index | 65.8 % | Qtr Profit Var | 666 % | EPS | 283 ₹ | Industry PE | 31.6 |
📊 Analysis: NEULANDLAB shows strong intraday potential. Current price (₹16,759) is above DMA 50 (₹15,375) and DMA 200 (₹14,440), reflecting bullish momentum. RSI at 59.4 indicates healthy strength, while MACD (544) confirms strong upward bias. Volume (30K) is below the 1-week average (49K), showing reduced participation. Fundamentals remain attractive with EPS of ₹283, strong ROE (21.5%) and ROCE (26.6%), though valuation is stretched with P/E (59.3 vs industry 31.6) and PEG ratio (1.95).
💹 Optimal Buy Price: ₹16,700–16,800 if sustained above VWAP with strong volume.
🎯 Profit Exit Levels: ₹17,000 (near resistance) and ₹17,300–17,500 (next resistance zone).
🛑 Stop-Loss: ₹16,500 (below intraday support).
⏱️ If Already Holding: Exit near ₹17,000–17,500 if RSI approaches 65–68 or momentum slows. Cut positions if price breaks below ₹16,500 with rising volume pressure.
Positive
- Strong ROE (21.5%) and ROCE (26.6%) highlight efficiency.
- EPS of ₹283 supports valuation strength.
- Price trading above DMA 50 and DMA 200, confirming bullish bias.
- DII holding increased (+1.12%), showing domestic institutional confidence.
- Quarterly PAT surged (₹40.4 Cr → ₹213 Cr).
Limitation
- High P/E (59.3) compared to industry average (31.6), indicating overvaluation.
- PEG ratio (1.95) suggests stretched growth-adjusted pricing.
- Dividend yield at 0.07% is negligible.
- FII holding decreased (-0.44%), showing weaker foreign sentiment.
- Volume below average, reducing intraday conviction.
Company Negative News
- FII outflows highlight weaker foreign confidence.
- Valuation premium raises caution for traders.
Company Positive News
- Quarterly PAT surged significantly (+666%).
- DII inflows (+1.12%) reflect strong domestic confidence.
- Strong fundamentals with high efficiency metrics.
Industry
- Industry P/E at 31.6, much lower than NEULANDLAB’s 59.3, highlighting valuation premium.
- Pharma sector remains resilient with long-term demand drivers.
Conclusion
⚖️ NEULANDLAB offers strong intraday trading potential with bullish technicals and robust fundamentals but faces valuation pressure and weaker foreign sentiment. Suitable for trades above ₹16,700 with profit targets near ₹17,000–17,500 and strict stop-loss at ₹16,500. Momentum indicators suggest cautious optimism as RSI remains in a healthy zone.
Would you like me to extend this into a swing trade analysis with 1–2 week holding logic, or keep it strictly intraday-focused?